Payment overview · 2025
General Payments
$1,608.78
84 reported records · 22 companies
Healthcare provider profile · identity verified
Robert Czyzewski, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · EDISON, NJ · NPI 1558304782
Verified facts
What the public records show
CMS Open Payments records show Robert Czyzewski, M.D. received $1,608.78 in general payments during 2025 across 84 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Veltassa.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $318.58 | 19.8% | 9 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $173.13 | 10.8% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $160.24 | 10.0% | 9 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $120.30 | 7.5% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $119.09 | 7.4% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $93.22 | 5.8% | 5 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $91.36 | 5.7% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $64.81 | 4.0% | 4 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $63.05 | 3.9% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $54.96 | 3.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.49 | 3.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.16 | 3.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.79 | 2.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.62 | 2.3% | 2 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $35.59 | 2.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.84 | 2.0% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $27.58 | 1.7% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $18.21 | 1.1% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $17.07 | 1.1% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $16.42 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.25 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.02 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,608.78 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $302.66 | 8 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $173.13 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $160.24 | 9 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $119.09 | 7 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $91.36 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $64.81 | 4 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $58.29 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $54.96 | 3 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $49.49 | 3 | 2025 |
Source payment records
|
|||||
| QSYMIA Normalized: qsymia |
Drug | VIVUS LLC | $47.51 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $36.79 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $35.59 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $31.27 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 368 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
368 | 95 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
31 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 521 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 519 | 132 |
| Furosemide | Furosemide | 469 | 113 |
| Losartan Potassium | Losartan Potassium | 391 | 93 |
| Farxiga | Dapagliflozin Propanediol | 368 | 95 |
| Eliquis | Apixaban | 364 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 297 | 61 |
| Gabapentin | Gabapentin | 295 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 251 | 63 |
| Metformin Hcl | Metformin Hcl | 221 | 50 |
| Alprazolam | Alprazolam | 218 | 46 |
| Omeprazole | Omeprazole | 204 | 34 |
| Mirtazapine | Mirtazapine | 197 | 41 |
| Sertraline Hcl | Sertraline Hcl | 150 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 146 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 39 |
| Tramadol Hcl | Tramadol Hcl | 139 | 40 |
| Potassium Chloride | Potassium Chloride | 128 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 36 |
| Donepezil Hcl | Donepezil Hcl | 126 | 21 |
| Divalproex Sodium | Divalproex Sodium | 122 | 17 |
| Carvedilol | Carvedilol | 114 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 109 | 33 |
| Levofloxacin | Levofloxacin | 109 | 82 |
| Lisinopril | Lisinopril | 101 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 98 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 93 | 11 |
| Milrinone In 5% Dextrose | Milrinone Lactate/D5w | 92 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 21 |
| Famotidine | Famotidine | 84 | 28 |
| Memantine Hcl | Memantine Hcl | 83 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 22 |
| Prednisone | Prednisone | 80 | 37 |
| Midodrine Hcl | Midodrine Hcl | 79 | 31 |
| Celecoxib | Celecoxib | 78 | suppressed |
| Latanoprost | Latanoprost | 75 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 24 |
| Spironolactone | Spironolactone | 72 | 18 |
| Trazodone Hcl | Trazodone Hcl | 72 | 19 |
| Montelukast Sodium | Montelukast Sodium | 70 | 11 |
| Buspirone Hcl | Buspirone Hcl | 65 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 27 |
| Allopurinol | Allopurinol | 57 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | suppressed |
| Fentanyl | Fentanyl | 55 | suppressed |
| Januvia | Sitagliptin Phosphate | 55 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 13 |
| Clonazepam | Clonazepam | 53 | 17 |
| Jardiance | Empagliflozin | 53 | 18 |
| Levetiracetam | Levetiracetam | 53 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 22 |
| Naproxen | Naproxen | 47 | 24 |
| Simvastatin | Simvastatin | 47 | 14 |
| Clonidine Hcl | Clonidine Hcl | 43 | 17 |
| Atenolol | Atenolol | 41 | suppressed |
| Finasteride | Finasteride | 41 | 13 |
| Glimepiride | Glimepiride | 41 | 11 |
| Kerendia | Finerenone | 41 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 19 |
| Azithromycin | Azithromycin | 39 | 33 |
| Ezetimibe | Ezetimibe | 39 | 15 |
| Cefuroxime | Cefuroxime Axetil | 38 | 34 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Metolazone | Metolazone | 36 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 36 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 18 |
| Ramipril | Ramipril | 35 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 34 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 11 |
| Lokelma | Sodium Zirconium Cyclosilicate | 33 | 14 |
| Calcium Acetate | Calcium Acetate | 31 | 11 |
| Lactulose | Lactulose | 31 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 31 | 13 |
| Bumetanide | Bumetanide | 30 | suppressed |
| Nystop | Nystatin | 30 | 17 |
| Albuterol Sulfate | Albuterol Sulfate | 29 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Repaglinide | Repaglinide | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 12 |
| Diazepam | Diazepam | 24 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 24 | 18 |
| Ssd | Silver Sulfadiazine | 24 | 11 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 19 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Rayaldee | Calcifediol | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Prosol | Parenteral Amino Acid 20% No.1 | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,608.78 · 84 records | AstraZeneca Pharmaceuticals LP | ACTHAR, AREXVY, BENLYSTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FUROSCIX, Fabhalta, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, Korlym, LEQVIO, Ozempic, PANCREAZE, PURIFIED CORTROPHIN GEL, QSYMIA, SHINGRIX, TARPEYO, VELPHORO, Veltassa, Yorvipath | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error